Tango Therapeutics Inc

Research Tango Therapeutics Inc (TNGX) on Bullrun: market cap USD 4.71B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTNGX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 4.71B
• Financial periodFY2025
• RevenueUSD 62.38M
• Revenue growth48.3%
• Net income-USD 101.60M
• Free cash flow-USD 139.93M

Valuation Snapshot

latest market cap is USD 4.71B.

About Tango Therapeutics Inc

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.

Frequently asked questions

What is Tango Therapeutics Inc's market cap?

Tango Therapeutics Inc's market capitalization is USD 4.71B.

What does Tango Therapeutics Inc do?

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.